627 related articles for article (PubMed ID: 31140385)
41. Conservative management of patients with intrathyroidal well-differentiated follicular thyroid carcinoma.
Saadi H; Kleidermacher P; Esselstyn C
Surgery; 2001 Jul; 130(1):30-5. PubMed ID: 11436009
[TBL] [Abstract][Full Text] [Related]
42. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival.
Lo CY; Chan WF; Lam KY; Wan KY
Ann Surg; 2005 Nov; 242(5):708-15. PubMed ID: 16244545
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
Wu MH; Shen WT; Gosnell J; Duh QY
Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
[TBL] [Abstract][Full Text] [Related]
44. Modified dynamic risk stratification system further predicts individual outcome in patients with intermediate-risk papillary thyroid cancer.
Cuéllar DI; De Los Reyes A; Llamas-Olier A
Ann Endocrinol (Paris); 2023 Apr; 84(2):242-248. PubMed ID: 35483449
[TBL] [Abstract][Full Text] [Related]
45. Evaluating Disease-specific Survival Prediction of Risk Stratification and TNM Systems in Differentiated Thyroid Cancer.
van Velsen EFS; Peeters RP; Stegenga MT; van Kemenade FJ; van Ginhoven TM; van Balkum M; Verburg FA; Visser WE
J Clin Endocrinol Metab; 2023 May; 108(6):e267-e274. PubMed ID: 36508298
[TBL] [Abstract][Full Text] [Related]
46. Comparison of presentation and clinical outcome between children and young adults with differentiated thyroid cancer.
Wang JT; Huang R; Kuang AR
Asian Pac J Cancer Prev; 2014; 15(17):7271-5. PubMed ID: 25227827
[TBL] [Abstract][Full Text] [Related]
47. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
48. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
49. [Differentiated thyroid carcinoma, 1972-1992. Follow-up, detection of recurrences and prognostic factors].
Obiols G; Simó R; Burgos R; Tresserras R; Galofré P; Masmiquel L; Hernández C; Mesa J
Med Clin (Barc); 1997 Nov; 109(19):738-43. PubMed ID: 9470182
[TBL] [Abstract][Full Text] [Related]
50. Dynamic Risk Stratification in Stage I Papillary Thyroid Cancer Patients Younger Than 45 Years of Age.
Sung TY; Cho JW; Lee YM; Lee YH; Kwon H; Jeon MJ; Kim WG; Choi YJ; Song DE; Chung KW; Yoon JH; Hong SJ
Thyroid; 2017 Nov; 27(11):1400-1407. PubMed ID: 28847226
[TBL] [Abstract][Full Text] [Related]
51. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
[TBL] [Abstract][Full Text] [Related]
52. Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.
Lang BH; Wong KP; Cheung CY; Wan KY; Lo CY
Ann Surg Oncol; 2013 Apr; 20(4):1329-35. PubMed ID: 23104708
[TBL] [Abstract][Full Text] [Related]
53. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
[TBL] [Abstract][Full Text] [Related]
54. Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors.
Russo M; Malandrino P; Moleti M; Vermiglio F; D'Angelo A; La Rosa G; Sapuppo G; Calaciura F; Regalbuto C; Belfiore A; Vigneri R; Pellegriti G
Pediatr Blood Cancer; 2018 Sep; 65(9):e27226. PubMed ID: 29768715
[TBL] [Abstract][Full Text] [Related]
55. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm.
Holoubek SA; MacKinney EC; Khokar AM; Kuchta KM; Winchester DJ; Prinz RA; Moo-Young TA
Surgery; 2022 Jan; 171(1):203-211. PubMed ID: 34384604
[TBL] [Abstract][Full Text] [Related]
56. Rising incidence of small size papillary thyroid cancers with no change in disease-specific survival in Finnish thyroid cancer patients.
Hakala T; Kellokumpu-Lehtinen P; Kholová I; Holli K; Huhtala H; Sand J
Scand J Surg; 2012; 101(4):301-6. PubMed ID: 23238509
[TBL] [Abstract][Full Text] [Related]
57. Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome.
Ciappuccini R; Heutte N; Lasne-Cardon A; Saguet-Rysanek V; Leroy C; Le Hénaff V; Vaur D; Babin E; Bardet S
BMC Cancer; 2020 Aug; 20(1):765. PubMed ID: 32799836
[TBL] [Abstract][Full Text] [Related]
58. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
[No Abstract] [Full Text] [Related]
59. Recurrence factors and prevention of complications of pediatric differentiated thyroid cancer.
Wang C; Chen X; Wei X; Chen F; Wang Y; Shen Z
Asian J Surg; 2017 Jan; 40(1):55-60. PubMed ID: 27697309
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.
Lang BH; Lo CY; Chan WF; Lam KY; Wan KY
Ann Surg Oncol; 2007 Feb; 14(2):730-8. PubMed ID: 17103065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
